PRRT2 and psoriasis: First‐generation PKCθ inhibitors such as sotrastaurin have shown efficacy in psoriasis; however, their low oral bioavailability (approximately 17%), poor metabolic stability, and significant off‐target effects due to low kinase selectivity have limited their clinical use.